Syros Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Syros Pharmaceuticals

01/11/2021 13:00

* Syros Pharmaceuticals Inc  SYRS.OQ   SYRS.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 5. 
* The Cambridge, Massachusetts-based company is expected to
report  a 17.3% increase in revenue to $4.49 million from $3.83
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Syros Pharmaceuticals
Inc is for a loss of 44 cents per share. For the same quarter
last year, the company reported a loss of 43 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Syros
Pharmaceuticals Inc is $18​, about 77.1% above​ its last closing
price of $4.13. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.37       -0.37      -0.36     Beat    3.3
 Mar. 31 2021  -0.46       -0.46      -0.23     Beat    50.5
 Dec. 31 2020  -0.59       -0.50      -0.62     Missed  -24.2​
 Sep. 30 2020  -0.38       -0.38      -0.43     Missed  -11.9
 Jun.          -0.40​      -0.40      -0.38     Beat    5.5​
 30​ 2020​                                              
 Mar. 31 2020  -0.44       -0.43      -0.39     Beat    10.1​
 Dec. 31 2019  -0.48       -0.47      -0.46     Beat    1.8
 Sep. 30 2019  -0.48       -0.48      -0.47     Beat    1.9
 This summary was machine generated November 1 at 13:00 GMT.  All
figures in US dollars unless otherwise stated